In adults with type 2 diabetes on metformin, myocardial blood flow was lower with liraglutide alone than in the insulin-treated groups.
In plain wordsIn adults with type 2 diabetes, heart blood flow was lower with liraglutide alone than in the groups that received insulin.
- Peptide
- Liraglutide
- Outcome
- DecreaseMyocardial blood flow
- Study
n: not reported in source
- Comparator
- Insulin detemir groups (detemir; detemir plus liraglutide)
- Outcome group
- Heart function · Cardiovascular
- Studied dose
- Dose not stated · 3 monthsAs given in this study (human).
Measurements
- MBF median
- 0.52 mL/g/min
- liraglutide
- MBF median
- 0.64 mL/g/min
- detemir
- MBF median
- 0.75 mL/g/min
- detemir plus liraglutide
Source sentences
MBF was greater in the insulin-treated groups [median (25th, 75th percentile): detemir, 0.64 mL/g/min (0.50, 0.69); liraglutide, 0.52 mL/g/min (0.46, 0.58); detemir plus liraglutide, 0.75 mL/g/min (0.55, 0.77); P = 0.035 comparing three groups, P = 0.01 comparing detemir groups to liraglutide alone].
1 context sentence(design, population, supporting numbers)
In a randomized clinical trial of patients with T2D treated with metformin plus oral agents or basal insulin, myocardial fuel use was compared after 3 months of treatment with insulin detemir, liraglutide, or combination detemir plus liraglutide added to background metformin.